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a b s t r a c t 
Developing and distributing a safe and effective SARS-CoV-2 (COVID-19) vaccine has garnered immense 
global interest. Less than a year after COVID-19 was declared a pandemic, several vaccine candidates had 
received emergency use authorization across a range of countries. Despite this scientific breakthrough, the 
journey from vaccine discovery to global herd immunity against COVID-19 continues to present significant 
policy challenges that require a collaborative, global response. We offer a framework for understanding 
remaining and new policy challenges for successful global vaccine campaigns against COVID-19 as well 
as potential solutions to address them. Decision-makers must be aware of these challenges and strategize 
solutions that can be implemented at scale. These include challenges around maintaining R&D incentives, 
running clinical trials, authorizations, post-market surveillance, manufacturing and supply, global dissem- 
ination, allocation, uptake, and clinical system adaption. Alongside these challenges, financial and ethical 
concerns must also be addressed. 
© 2021 The Author(s). Published by Elsevier B.V. 

































Immense global interest has risen around the development and 
istribution of safe and effective SARS-CoV-2 (COVID-19) vaccines. 
o date, multiple vaccine candidates have received authorizations 
or emergency use and many countries have initiated vaccination 
ollout effort s. Vaccines being developed, manufactured, and de- 
ivered in under a year is a notable scientific feat – enough so 
hat Science Magazine named this the top breakthrough of 2020 
1] . However, from ensuring continued development of vaccine 
andidates, to authorizing, producing, distributing, administering, 
nd monitoring existing ones, the COVID-19 vaccine process re- 
ains laden with policy challenges. While literature tends to ex- 
lore these challenges in siloes, these issues are inherently over- 
apping and interdependent. As such, we offer a framework for un- 
erstanding 11 of the remaining and new policy challenges related ∗ Corresponding author. 
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ddress them. 
The framework, as illustrated in Fig. 1 , consists of three main 
D’-dimensions of achieving widespread global COVID-19 immunity 
ia vaccinations. The three D’s are ‘development’, ‘dissemination’, 
nd ‘deployment’: ensuring the continued development of safe and 
ffective vaccines, supplying and disseminating the vaccine around 
he world, and deploying the vaccine within countries. Under these 
imensions, there are 11 challenges to achieving these goals: main- 
aining strong and sensible R&D incentives; running coordinated 
linical trials; authorizing safe and effective vaccines efficiently and 
ransparently; monitoring effectiveness during (and after) vaccine 
eployment; ensuring equitable vaccine access globally; manufac- 
uring sufficient quantities and maintaining supply chain capac- 
ty; safely and securely transporting and delivering vaccines; deter- 
ining fair vaccine allocation; encouraging the uptake of vaccines; 
thical implications of vaccine passports and other vaccine require- 
ents; and adapting clinical and health research systems. Financ- 
ng decisions and ethical considerations will also need to be made 
rom the start of vaccine R&D through to clinical system adapta- under the CC BY license ( http://creativecommons.org/licenses/by/4.0/ ) 
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ions. As such, these are represented as cross-cutting challenges in 
he framework. 
. Ensuring continued development of safe and effective 
accines 
While several vaccines have recently gained (or are on the cusp 
f gaining) emergency use authorizations from countries around 
he world, the end of the pandemic is still a way off: many of 
he first generation vaccines require ultra-cold chain technology 
nd are expensive, proving significant hurdles to global vaccina- 
ion campaigns, and especially in low- and middle-income coun- 
ries (LMICs); furthermore, we still do not know how long vac- 
ines will remain effective in individuals over time; and the rise 
f new variants pose concern over mutations with high vaccine 
scape potential. As such, governments must continue to develop 
ew vaccines and optimize their safety, effectiveness, and quality. 
e identified four primary challenges involved in achieving this: 
aintaining strong research and development incentives; running 
oordinated clinical trials; authorizing safe and effective vaccines 
fficiently and transparently; and continuing to monitor their im- 
acts as (and after) they are deployed. Importantly, each of these 
hallenges will require greater public engagement and intergovern- 
ental cooperation and support in the redesign of incentives, in- 
titutions, and processes. 
.1. Maintaining strong and sensible R&D incentives 
In early December 2020, less than one year after the start of the 
andemic, COVID-19 vaccines were already gaining authorizations 
n countries around the globe. This feat would not have been possi- 
le without the tremendous effort, collaboration, partnership, and 
nancial support that went into the development of these prod- 
cts. However, even though a handful of vaccines are already be- 
ng administered in countries around the world, more options on 
he market are necessary to vaccinate the billions and billions of 
eople needed for herd immunity. 554 For these first-generation vaccines, governments used both 
ush mechanisms (i.e. direct grants to companies) and pull mecha- 
isms (i.e. Advanced Market Commitments) to stimulate R&D with- 
ut ties to quality or efficacy of eventual vaccine products – an un- 
erstandable short-term solution given the situation in 2020. How- 
ver, COVID-19 is unlikely to disappear soon, and we must now 
onsider longer-term effort s. We are nowhere near the vaccine ad- 
inistration levels needed for global herd immunity, new variants 
f concern are emerging [2] , and we still do not know how long 
urrent vaccines remain effective and whether yearly or other pe- 
iodic boosters are necessary. Incentive structures should undergo 
ystemic changes so that manufacturers continue to search for vi- 
ble candidates. 
It is unlikely that all remaining and future vaccine candidates 
ill meet efficacy thresholds for clinical trials. We have already 
een the withdrawal of several candidates – even ones from major 
harmaceutical developers [3] . Continued incentives are needed to 
aintain robust R&D efforts to ensure vaccine effectiveness, saf ety, 
nd quality, and to generate second and third generation vaccines 
o meet the ever-changing needs of populations across the globe. 
ith the emergence of new variants, there is also a rise in inter- 
st around the development of a “universal ‘variant-proof’ vaccine, 
ble to fend off different varieties of the same virus family” [4] . 
he challenge of maintaining strong R&D incentives is bolstered 
y the nature of vaccine development, which presents higher costs 
nd risk relative to other pharmaceuticals [5] . Governments and 
onors could consider implementing additional financing mecha- 
isms to encourage R&D, including patent purchasing [6] , patent 
ooling, and bonds [7] . The Options Market for Vaccines (OMV) 
odel (based on the Options Market for Antibiotics model), where 
urchasers would make financial investments into COVID-19 vac- 
ine R&D in exchange for reduced future prices, has been proposed 
s a potentially effective way to combine push and pull incentives 
or vaccine development in the current pandemic setting [ [5 , 8–10] . 
EPI has already received some political backing for its proposal to 
peed up the development time of new vaccines to 100 days; but 
t will need substantial international and financial support to reach 
his ambitious goal [11] . 
























































































































In late 2020, European Commission president Ursula von der 
eyen announced that a European equivalent to the US Biomedical 
dvanced Research and Development Authority (BARDA) would be 
stablished in efforts to better prepare for future disease outbreaks 
the European Health Emergency Preparedness and Response Au- 
hority (HERA) [12] . However, there are still few details on how 
ERA will be funded, governed, and if it will utilize innovative fi- 
ancing methods such as the OMV model described above to in- 
entivize R&D and guarantee fair prices [13 , 14] . 
.2. Running coordinated clinical trials 
Another challenge in the COVID-19 vaccine process is that gov- 
rnments and developers must decide how to set the standards for 
alid clinical trials in humans at unprecedented speeds. Developers 
ay also face tough decisions in determining whether they need 
o scrap or delay vaccine candidates for a disease that the world 
o desperately needs inoculations for. In December 2020, amidst 
ews celebrating the start of vaccine administration in the US and 
he UK, the University of Queensland had to abandon the develop- 
ent of one candidate after trial participants were receiving false- 
ositive HIV test results [15] . Sanofi and GSK also announced a de- 
ay to a vaccine candidate which was showing a good immune re- 
ponse in younger trial participants, but a low response in older 
atients [15] . Unless challenge trials – where study participants are 
ntentionally exposed to the infectious disease organism in ques- 
ion – are being utilized (such as the one recently initiated in the 
K [16] ), phase III vaccine trials must be undertaken in settings 
here there is sufficiently high levels of infection risk so that an 
ffect can be identified with a degree of confidence [17] . 
Methodological issues and communication errors in clinical tri- 
ls can lead to unrepresentative data and can even fuel vac- 
ine hesitancy. For example, some of the participants in the As- 
raZeneca/Oxford vaccine’s UK-based clinical trial received roughly 
alf of their intended first dose and additionally, the timing be- 
ween first and second doses varied between study participants, 
eading to criticism of the company’s initial 90% efficacy claim be- 
ause these levels were seen in those who did not receive the stan- 
ard regimen [18] . 
Additionally, within individual countries, clinical trials may not 
nclude adequate or representative sample sizes and demograph- 
cs. Clinical trials in HICs—especially challenge trials—have histori- 
ally included young, healthy participants with limited racial and 
thnic diversity, posing a significant barrier to generalizability [19] . 
s the burden of COVID-19 falls particularly on older, co-morbid, 
nd minority ethnic populations, it is essential that clinical trial 
articipants are diverse and representative of those in the general 
opulation who will receive the vaccines when they successfully 
eliver to market. AstraZeneca faced additional backlash upon the 
iscovery that in the clinical trial arm which reported 90% vac- 
ine effectiveness (where patients received a half-dose for the first 
njection), the trial participants were all aged 55 and below [18] . 
imited racial and ethnic diversity in clinical trials can also hin- 
er trust in vaccines among minority populations further down 
he line. According to the London School of Hygiene and Tropical 
edicine (LSHTM) COVID-19 vaccine tracker, more than 80% of the 
fizer/BioNTech Phase III clinical trial participants are White; 99% 
n the Gamaleya Phase III trial, 79% in Moderna’s; and 83% in the 
xford/AstraZeneca Phase III trials [20] . When incentives are at- 
ached to trial participation, careful ethical considerations must be 
ade to ensure that potential benefits to society outweigh the risk 
f harm imposed on trial participants—many of whom may be of 
ower socioeconomic status. 
The WHO took a commendable step by proposing a Solidarity 
accine Trial with an adaptive design (i.e., enabling participants 
o continually be added) and participants from multiple member 555 tates [21] . Pharmaceutical developers have also made unprece- 
ented strides in transparency effort s by publishing protocols and 
ata publicly [22] . However, there are still areas for improvement. 
linical trials for vaccines are often executed differently across dif- 
erent countries. To maximize statistical rigor, trials need broad 
onsensus, standardized protocols and transparency requirements, 
 challenge given the variations in regulatory regimes across coun- 
ries. The EU Clinical Trials Register was developed to do just that 
cross European countries [23] . However, with recent announce- 
ents about HERA, questions remain as to how these institutes 
ill coordinate and operate in practice [24] . Ultimately, govern- 
ents and international agencies should play a role in determining 
he thresholds and protocols for trials, while private sector indus- 
ry assists in financing the trials themselves. 
.3. Authorizing safe and effective vaccines efficiently and 
ransparently 
After the development of a viable vaccine, relevant health tech- 
ology assessment bodies need to authorize the product for emer- 
ency use or grant market licensure. So far, the regulatory agency 
rocesses have been disappointingly disjointed, and have come out 
ith different advice for the same vaccines and in different time 
rames. When reviewing 24 countries’ processes, researchers iden- 
ified more than 50 regulatory pathways to accelerated vaccine ap- 
roval [25] . Experts have called for more harmony and suggested 
hat broad agreement across regulators on definitions for differ- 
nt approval types could help pharmaceutical companies prepare 
rug applications more quickly and share and compare findings 
nd analyses more easily – in turn improving regulatory efficiency 
nd trust [26] . 
On 21 December, the European Medicines Agency (EMA) rec- 
mmended the Pfizer/BioNTech vaccine for a conditional market- 
ng authorization in the EU. By that point, the same vaccine had 
lready received some form of authorization in 15 countries; in- 
luding in the UK, US, and Canada [27] . Variation extends beyond 
egulatory approvals to differences in the conditions for accessing 
accines. Early on, the US [28] and the EU [29] accused the UK in
eing too quick to give the Pfizer/BioNTech vaccine the green light, 
laiming there was not enough data; however, weeks later the FDA 
nd the EMA had also granted emergency use authorizations for 
he same product, including for pregnant women. Meanwhile, the 
K still advises against COVID-19 inoculations in pregnant women 
nless they are considered high risk because of other health con- 
itions or occupation. The AstraZeneca/Oxford vaccine was recom- 
ended for use in all adults when it first received authorization in 
he UK. By contrast, several European countries implemented re- 
trictions against use of this vaccine in older people when they 
rst issued authorizations [30] . 
Beyond the variations in regulatory process length and the rec- 
mmendations made, the actual processes themselves vary. Some 
egulatory bodies, such as the FDA, use open forums to deliber- 
te and draw on their own statistical analyses based on raw data 
rom clinical trials, while others do not [26] . Several countries have 
uthorized vaccines without third stage trial data. For example, in 
he summer of 2020, the Russian Federation approved a vaccine for 
se while it was still in the first phase of testing and did not have
ny results [31] ; China authorized several vaccines for emergency 
se with only phase I and II trial data [32] ; and in late 2020, India
pproved emergency use of Covaxin while it was still undergoing 
hase III testing [33] . 
Many regulatory bodies have released plans for fast-tracking 
accines which have been modified to respond to new COVID-19 
ariants, but these also differ. FDA guidance for modified COVID-19 
accines requires two non-inferiority studies, one which shows im- 
unogenicity in previously unvaccinated, uninfected participants, 























































































































nd the other which shows immunogenicity in those who have re- 
eived the vaccine before [34] . The EMA guidance also expects this, 
ut additionally requires several other endpoints be met; for ex- 
mple, the lower bound of the 95% confidence interval in serocon- 
ersion rates for the variant compared to the parent strain cannot 
xceed −10%, and seroconversion rates must be at least four times 
n titer from pre- to post-vaccination [35] . 
This variation across licensing processes, data requirements, and 
utcomes can prove problematic – mitigating confidence and trust 
round the safety and effectiveness of vaccines, delaying success- 
ul inoculation campaigns, and more. Millions of doses of the As- 
raZeneca vaccine are piling up unused in Europe after the discrep- 
ncies in initial advice for use in older adults mentioned above 
ave fueled doubts around the vaccine [30] ; contributing to further 
lowdowns in the EU COVID-19 vaccination rollout. Thus, effort s 
hould be made to increase coordination and transparency across 
egulatory agencies. 
There has already been some progress in this area: researchers 
ighlight that in 2012, the WHO established the International 
oalition of Medicines Regulatory Authorities (ICMRA) so that 
egulators could share information and approaches [26 , 36] . The 
CMRA, now consisting of 29 countries, has a working group fo- 
used on coordinating COVID-19 vaccine monitoring effort s across 
ountries. But despite several ICMRA meetings held and statements 
eleased since April 2020 focused on aligning regulatory processes 
37] , the uncoordinated efforts described above have still arisen, 
ignaling that further progress can be made. Pathways by which 
egulators can exchange information “in the same units and about 
he same end points, and to make decisions based on the same 
ata” at similar speeds in a transparent and open fashion still need 
o be developed and agreed upon [26 , 36] . 
.4. Monitoring effectiveness during (and after) vaccine deployment 
n the general population 
Adequate post-marketing surveillance systems can help pro- 
ote continued confidence and uptake in vaccines. Governments 
eed mechanisms to closely monitor and evaluate data on effec- 
iveness and adverse events as vaccinations are introduced to a 
opulation. Once again, transparency and coordination of these 
rocesses are also required for success. It is key to determine what 
etrics are most useful to measure and monitor a vaccine’s qual- 
ty and effectiveness (e.g., transmission rates, case fatality, adverse 
ffects) and outline how these data can be reported in real-time 
o other nations. Effort s in monitoring COVID-19 vaccines have be- 
un in some countries [38] , but beyond these individual initiatives, 
n international body, such as the WHO, could be charged with 
oing further and standardizing protocols for efforts to monitor 
he safety and effectiveness of vaccines as they are administered 
round the world. Current evidence suggests that the authorized 
OVID-19 vaccines are very safe, and the risk of harmful side ef- 
ects is low [39] . Still, it is important to continue to form consor-
iums to monitor the safety and effectiveness of these products so 
hat improvements can be made to future vaccines and programs. 
eal-world evaluations of immunizations which discern the vac- 
ine’s impact alone from that in combination with nonpharmaceu- 
ical interventions (NPIs) such as shelter-in-place orders or social 
istancing could also be conducted. 
. Supplying the vaccine around the world 
As more vaccines are developed and authorized for emergency 
se, governments should prepare for the mass production and dis- 
ribution of the billions of doses that are required around the 
lobe, and can implement innovative solutions to scale up manu- 
acturing capacity. Already, we have seen supply chain disruptions, 556 ailures to meet expected delivery quantities and timelines [40] , 
nd immense global disparities [41] in vaccine access with some 
ven terming it a ‘vaccine apartheid’ [42] . Supplying and deliver- 
ng these vaccines around the world involves two key components: 
nsuring equitable vaccine access globally; and manufacturing suf- 
cient quantities and maintaining supply chain capacity. 
.1. Ensuring equitable vaccine access globally 
Before distribution occurs, tools and procedural government 
echanisms are needed to determine how many doses each coun- 
ry will secure and at what cost. This has become one of the 
ost politically-driven challenges in this paper. Unfortunately, is- 
ues such as “vaccine nationalism,” or refusal to distribute vac- 
ines across national borders, is preventing sufficient supply of 
accines globally. Many HICs have pursued their own agreements 
ith pharmaceutical companies for COVID-19 vaccines. These in- 
ividual, siloed deals do not typically lead to the best global pro- 
urement practices, and instead we have seen wealthier countries 
ecuring as many vaccine doses as possible; even when it hin- 
ers vaccine accessibility elsewhere. Several HICs have purchased 
nough doses to vaccinate their populations several times over: 
anada, for example, could fully vaccinate its population five times 
ver (585% possible vaccination coverage) in the (admittedly un- 
ikely) event that all the vaccines for which it has purchased doses 
re authorized for use [43] . Meanwhile, the total potential popu- 
ation that can be vaccinated in LMICs (including upper middle- 
ncome countries) is significantly smaller. According to the Duke 
lobal Innovation Center, outside of COVAX agreements, China has 
urchased enough potential vaccines to cover 4% of its population, 
lgeria’s and Syria’s coverage is listed at 0%, and the African Union 
as purchasing agreements for potential vaccines to cover 40% of 
ts population [41] . Some countries have even implemented export 
ans on vaccines [44] . 
In late-January 2021, approximately 40 million doses of the vac- 
ine had been administered in at least 49 high-income countries, 
ut just 25 doses had been given in one of the lowest-income 
ountries [45] . The economic ramifications of these access dispar- 
ties are significant. A study commissioned by the ICC Research 
oundation suggests that if LMICs continue to have inadequate ac- 
ess to COVID-19 vaccines, global economic losses could accumu- 
ate to between $1.2–9.2 trillion, and more than half of this could 
all on HICs [46] . Beyond the moral and economic arguments for 
lobal vaccine equity, there is also the scientific argument: leav- 
ng much of the global population unvaccinated could increase the 
ncidence of new variants; and the more variants that arise, the 
ore likely it is that one will have high vaccine escape poten- 
ial [47] . The continued emergence of new variants with high vac- 
ine escape potential would not just have negative implications for 
ealth and wellbeing of populations, but it would create further 
conomic consequences and set off a cycle of revaccination/booster 
ampaigns. 
The COVAX facility was established with the goal of accelerating 
OVID-19 vaccine development and manufacturing and to ensure 
quitable access to these immunizations for all countries. Co-led 
y CEPI, Gavi, and the WHO, COVAX is the vaccines pillar of the 
ccess to COVID-19 Tools (ACT) Accelerator. COVAX aims to secure 
t least two billion COVID-19 vaccine doses by the end of 2021, 
ith more than 60% of those going to 92 low-income countries 
48] . By late February, COVAX had secured $6.3 billion [49] and 
elivered its first doses to Africa, so it is certainly making progress 
owards its goals [50] . However, when considering the trillions of 
ollars HIC governments are putting into stimulus packages alone, 
t becomes evident that further financial investments into COVAX 
an and should be made. 




























































































































It has also been highlighted that small middle-income coun- 
ries could become the “missing middle” as they face many dis- 
dvantages in purchasing and obtaining the vaccine. These coun- 
ries often have low production capacity, may not be the first to 
enefit from the COVAX Initiative, and may lack the capacity to 
ignal demand internationally [51] . A question, then, is how gov- 
rnments can be incentivized to coordinate efforts and design a 
distributive manufacturing model” to purchase vaccines synergis- 
ically? One method may be for international agencies to subsidize 
ountries with low population sizes but high manufacturing capa- 
ilities, so they can drive manufacturing effort s f or countries with 
reater demand. 
Several HICs have committed to donating some of their ex- 
ess vaccine doses to LMICs – however, most are waiting un- 
il significant portions of their own populations are offered jabs 
efore passing them across borders. Previous experience show 
hat international vaccine donations involve many political, regu- 
atory, indemnification, and liability complexities; experts suggest 
hat plans should be established for COVID-19 donation processes 
ooner rather than later so that no country is caught off guard [52] . 
Pricing of the COVID-19 vaccines has also come into question. 
eports suggest there is wide variation in price across different 
ountries, with poorer, smaller countries and those with lower pur- 
hasing power paying the most [53 , 54] . For example, Saudi Arabia, 
ganda, and South Africa are paying more than $5 per dose for 
he Oxford/AstraZeneca vaccine, and the European Commission is 
aying $3.50 per dose [54] . The company, which has committed 
o selling the vaccine without profit during the pandemic period, 
uggests that these price differences reflect differences in manufac- 
uring factors. However, large price differentials exist for several of 
he other vaccines, and questions have been raised as to whether 
hese are always justified, especially for vaccines that have been 
eavily subsidized by governments. Innovative financing R&D mod- 
ls which link a product’s price to the initial investments and risks 
aken by a purchaser as well as the value of that product, such 
s the OMV model, could help us move to fairer and more sus- 
ainable pricing. This will become increasingly important if regular 
OVID-19 vaccination/booster campaigns are necessary to address 
ew virus variants or waning vaccine efficacy over time, such as is 
he case with the seasonal flu. 
.2. Manufacturing sufficient quantities and maintaining supply 
hain capacity 
Because of the unprecedented demand for a COVID-19 vaccine, 
anufacturing capacity must be scaled in parallel with effort s to- 
ards vaccine discovery. This winter, the EU faced serious supply 
hortages, and political pressure on leaders mounted [55] . The sup- 
ly challenges are even greater in many LMICs. Manufacturing ca- 
acity and supply chains should be strengthened, and quickly. At 
urrent rates, billions of people around the world might not have 
ccess to their first vaccinations until 2023 or 2024 [56] . 
Experts suggest that added capacity for three billion vaccines 
nnually could have a global benefit of $17.4 trillion [57] . Some 
arly investments in manufacturing capabilities for vaccines were 
ade while clinical trials were still underway. This has been very 
mportant as it has enabled vaccine production to begin without 
elay as soon as the products are authorized. However, HICs have 
igned the majority of bilateral deals for these first-generation 
accines, and thus these early production capacity investments are 
argely benefiting wealthier countries at present. At the start of 
021, the People’s Vaccine Alliance estimated that all of Moderna’s 
xpected vaccine production for 2021 and 96% of Pfizer’s was 
lready reserved by rich nations [45] . However, it is not too late 
o make further investments in manufacturing capacity that can 
enefit LMICs: recent models constructed by Castillo et al. suggest 
hat “Even assuming a lag of several months…Adding capacity for 557  billion annual courses to the baseline 3 billion would avert $576 
illion in comprehensive losses if the capacity comes only in July 
nd $989 billion if the capacity comes online in April…and would 
peed up completion of widespread vaccination by over 4 months”
57] . 
Exchanges of intellectual property or technical know-how are 
ikely to be controversial in the profit-making pharmaceutical in- 
ustry; but these may be essential to scale up manufacturing ca- 
acity. One of the least controversial methods for this (perhaps) is 
 technology transfer whereby the original pharmaceutical product 
eveloper agrees to let another company manufacture its vaccine. 
nder normal circumstances, these partnerships are highly uncom- 
on, but to-date several companies have already agreed to man- 
facture COVID-19 vaccines from other pharmaceutical develop- 
rs which have successfully attained emergency use authorizations 
or are on the cusp of doing so) [58] . Other proposals have been
ade which suggest governments should be able to jointly pur- 
hase patent rights for COVID-19 vaccines so that developers are 
ewarded for their innovative efforts and incentivized to engage in 
uture work, while simultaneously, countries can manufacture and 
istribute doses to their populations [59] . Alternative suggestions 
nclude the introduction of contractual provisions on installing new 
apacity for vaccine buyers and the soliciting of bids [57] . Further- 
ore, an increasing number of countries are calling for compulsory 
icensing of COVID-19 vaccine patents so that they can manufac- 
ure and supply these products domestically [60] . However, some 
xperts highlight that if intellectual property rights were removed 
his could open concerns around quality control (which could in 
urn increase vaccine hesitancy), and also suggest that even if in- 
ellectual property barriers were removed, many countries still will 
ot be able to produce them without proper knowledge transfer 
rom originators [61] . 
Alongside the manufacturing of the vaccines themselves, other 
elated equipment must also be produced. Vaccines requiring cold- 
hain supply or other complex supply chain systems, present 
dded challenges for countries without adequate existing infras- 
ructure. And this will be even more difficult in countries with 
isruptions to supply chains because of conflict or natural disas- 
ers. About 20% of the world’s poorest countries do not have ade- 
uate cold chain capacity [62] , and while some countries do have 
quipment, in many instances it is old or broken and unable to 
eep vaccines cool. In late-June, the Gavi Board agreed to investi- 
ate how its Cold Chain Equipment Optimization Program (CCEOP) 
ould be expanded to grow cold chain capacity in LMICs to meet 
OVID-19 vaccine demand [63] . 
Global shortages of and competition for glass vials and syringes 
ay also serve as bottlenecks for large-scale immunizations [64] . 
eyond export bans on COVID-19 vaccines themselves, those on 
aterials like bags and filters, can lead to shortages of medical 
roducts all over the world because today’s supply chains are so 
nterdependent and global; and these can have impacts on health 
reas outside of COVID-19 [65] . Various stakeholders should con- 
ribute to planning and building supply chain resiliency amongst 
ountries lacking infrastructure. Countries must also acknowledge 
hat supply chains are global, and a disruption anywhere will im- 
act necessary vaccine campaigns everywhere. Most manufactur- 
ng efforts thus far have been made by private sector investors, 
uggesting an opportunity for governments and international agen- 
ies to play a larger role in incentivizing manufacturing. One fis- 
ally sustainable way to achieve this might be for governments to 
urchase equity in the production of vaccines or share some of the 
ventual profits of successfully approved vaccines. Governments 
nd international agencies may also consider insurance mecha- 
isms for pharmaceutical companies that indemnify losses in the 
ase of failed marketing authorizations in exchange for early de- 











































Overview of current phase II/III, III, and IV COVID-19 vaccine candidates (as of 5 March 2021). 





































AG0302-COVID19 Anges, Takara Bio, 
Osaka University 








530 May-21 Pending No Pending No – N/A 
ZF2001 Anhui Zhifei 
Longcom 
Biopharmaceuti- 










30,216 Apr-22 Pending No Pending; 2 
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58,166 Mar-21 3 billion Yes 2 to 8 °C Yes Early/Emergency 
Use in numerous 
countries incl. 
UK, EU, India, 
Argentina, 
Dominican 
Republic, and El 
Salvador 
7 







Efficacy 26,679 Mar-21 Up to 700 
million doses 
No 2 to 8 °C Yes Emergency Use 
in India 
N/A 












42,382 Dec-21 Pending No Pending; 2 
to 8 °C or 
-15 to 25 °C 

















22,150 Jul-22 Up to 1 billion 
doses 
No 2 to 8 °C No – N/A 










7,380 Mar-23 Up to 1 billion 
doses 
No 2 to 8 °C No – N/A 





40,674 Mar-21 300 million No 2 to 8 °C No – 2 














































Table 1 ( continued ) 
NAME DEVELOPERS A 
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Efficacy 1,321 Sep-22 > 100 million 
doses 
No Room Temp No – N/A 
CAMS VACCINE Institute of 
Medical 









35,433 Sep-21 Pending No Pending; 2 















Efficacy 77,034 Jan-21 1 billion Yes 2 to 8 °C Yes Early/Emergency 









32,016 Dec-21 80 million 
doses 
No 2 to 8 °C No – N/A 
mRNA-1273 










34,320 Oct-22 Up to 1 billion No 2 to 8 °C for 
up to 30 
days; -15 to 




Use in numerous 
countries, 
including USA, 
Canada, EU, UK, 
and Israel 
2 














































Table 1 ( continued ) 
NAME DEVELOPERS A 




































NVX-COV2373 Novavax 3 Protein 
subunit Observer- 
blind 
Efficacy 50,819 Mar-21 2 billion Yes 2 to 8 °C No – 7 
BNT162 B1/B2 Pfizer/BioNTech + 
Fosun Pharma 








51,358 Aug-21 Up to 2 billion Yes -60 to -80 °C Yes Full/Emergency 









QAZCOVID-IN Research Institute 
for Biological 
Safety Problems, 








3,244 Mar-21 Pending No Pending; 2 




No – N/A 
BBIBP-CorV Sinopharm + 
China National 
Biotec Group 








Efficacy 56,128 Dec-21 Up to 1 billion No 2 to 8 °C Yes Full/Emergency 





















Efficacy 52,864 Mar-21 Up to 600 
million 
No Pending; 2 




Yes Limited use in 
China and UAE 
N/A 








Efficacy 35,633 May-21 Up to 1 billion No Pending; 2 













A The 5 March 2021 WHO COVID-19 Vaccine Landscape Tracker was consulted to identify COVID-19 vaccine candidates in phase II/III, III, and IV trials. One candidate, Zydus Cadila’s ZyCoV-D was excluded from this list because 
only Phase I/II data could be found in the public domain. B Information on Mechanism of Action, Total Participants Registered, Manufacture Projections, Storage Temp Requirements, whether it was In Use, and Countries Reporting 
Use was extracted from the LSHTM COVID-19 Vaccine Tracker (last updated 15 March 2021). C Trial Design and Primary Completion Date Information were also derived from the LSHTM COVID-19 Vaccine Tracker, but for the 
latest and largest trial only (last updated 15 March 2021). D Primary outcomes were identified from publicly available clinical trial information listed on ClinicalTrials.gov (last updated 15 March 2021). E COVAX profile inclusion 
information came from two separate announcements issued by the agency in 2020 and 2021. F ONE Vaccine Access Test scores came from the March 2021 ONE Vaccine Access Test 2.0 Report. Further details and references for 




























































































































. Deploying the vaccine within countries 
After a government secures an appropriate supply of vaccines, it 
ust take a whole systems approach to ensure fairness and equi- 
ability. This goal presents five primary challenges: safely and se- 
urely transporting and delivering vaccines, determining fair vac- 
ine allocation, encouraging the uptake of vaccines, ethical impli- 
ations of vaccine passports and other vaccine requirements, and 
dapting clinical systems. 
.1. Safely and securely transporting and delivering the vaccine 
An important element in the COVID-19 vaccine deployment 
rocess which has not received widespread attention to-date is se- 
urity [66] . From the factory all the way to the patient’s shoulders 
hey were meant for, vaccines must be protected against theft and 
ampering. At the end of 2020, Interpol issued a global alert that 
riminal activity aimed at infiltrating and disrupting supply chains 
nd spreading misinformation about fake cures via fake websites 
as likely to arise [67] . COVID-19 vaccines of unknown origin and 
uthenticity have been listed on the black market for over $200 
er dose [68] . In response to these threats, freight companies have 
amped up security effort s to minimize risks of COVID-19 vaccine 
argo tampering; they are selecting experienced drivers and con- 
ucting enhanced background checks, utilizing remotely operated 
igital locks, installing loud alarm systems, ensuring that vial pal- 
ets are unmarked, closely tracking shipments, and even holding 
raining on responding to vaccine cargo attacks for drivers [68] . 
ot only do security systems need to stop cargo from being stolen, 
ut they also must prevent any disruption to the supply chain that 
ould threaten the integrity of the cargo. Governments must con- 
inue to ensure security effort s are upheld where they have already 
een initiated, and implement plans and protocols in places where 
hey have not. 
.2. Determining fair vaccine allocation 
Since few countries have enough vaccines at hand to offer in- 
culations to their entire adult populations, governments are faced 
ith the tough task of determining and defining priority groups 
or vaccination. As many have pointed out, “unequal access and 
accine availability risks exacerbating health inequalities,” [69] so 
hese decisions are not to be taken lightly. Across most countries, 
lder adults and frontline health and social care workers are high 
n prioritization guidance lists. For example, the first three groups 
o be offered the vaccine in the UK were 1) residents in a care
ome for older adults and staff working in care homes for older 
dults; 2) all those 80 years of age and over and frontline health 
nd social care workers; and 3) all those 75 years of age or older 
70] . This is similar to the recommendations released by the CDC 
ederal Advisory Committee on Immunization Practices on 1 De- 
ember 2020 to vaccinate healthcare workers and long-term care 
acility residents and workers in the first (1a) stage (although de- 
isions are ultimately made at the state level) [71] . COVAX lists 
ealthcare workers, older adults, and people with serious chronic 
onditions as target populations for the first stage of its vaccine 
eployment [72] . However, there are still differences: for example, 
he UK’s Joint Committee on Vaccination and immunization (JCVI) 
as stuck to a strict age-based prioritization scheme, while the CDC 
nd the WHO have occupational group-based prioritization guid- 
nce. 
Even with these prioritization groups outlined at the national 
evel, allocation decisions ultimately are dependent on the needs, 
isks and wants of a given population; the resources available (cold 
hain supply, personnel to administer it); and the logistics in- 
olved. For example, all doses of the Pfizer/BioNTech and Moderna 561 accines must be used (or disposed of) within six-hours once a vial 
s opened. In many instances, this has led to healthy young individ- 
als – who are far from reaching their spots in eligibility queues –
eceiving jabs that would have otherwise gone into the waste bin 
73] . Even when considering one priority group, such as frontline 
ealthcare workers, important decisions need to be made: for ex- 
mple, whether one healthcare facility should receive jabs before 
nother or if older workers in a facility should be vaccinated be- 
ore younger ones, etc. [74] . Additionally, it is important to con- 
ider equity across and within priority groups (i.e., to account for 
xisting ethnic and socioeconomic disparities in any scheme and 
rioritize groups that are historically underserved) [75 , 76] . Further- 
ore, mechanisms need to be established to capture groups that 
ay otherwise be missed within prioritization schemes, including 
ndocumented migrants or homeless individuals. 
.3. Encouraging the uptake of vaccines 
Prior to licensure, COVID-19 vaccines should endure rigorous 
esting and procedures and information about these tests should 
e transparent and accessible to reassure the public about safety 
nd efficacy. Otherwise, things such as the above-mentioned differ- 
nces in regulatory advice and requirements can lead to suspicions 
nd doubt around immunizations. 
Numerous surveys show that significant portions of populations 
ould refuse or are uncertain they would receive a COVID-19 vac- 
ine if it were available to them/their children [77–80] . In part, 
his may be driven by conspiracies, misinformation, and a growing 
nti-vax movement. However, it is important to acknowledge that 
accine hesitancy is different from anti-vax sentiment and can be 
riven by both rational and irrational reasoning. In the age of social 
edia and online information, fake news and misreporting on the 
afety of vaccines can spread rapidly, creating an ‘infodemic’ and 
ncreasing both anti-vax movements and vaccine hesitancy [81] . 
hroughout the pandemic, we have seen a slew of misinformation 
preading from political leaders and celebrities, which is also fu- 
ling the infodemic fire [82] . To try to combat this, social media 
ompanies are attempting to fact-check and demote disinforming 
osts on their platforms [83] . However, reports highlight that these 
ffort s have not been entirely successful and disinformation is still 
preading [84] . Now that vaccines are becoming more widely avail- 
ble, policymakers and the scientific community can increase pub- 
ic trust through clear communication in order to squash anti-vax 
isinformation [69 , 85] . Partnerships between social media compa- 
ies and influencers, governments, and international organizations 
an increase the amount of informative, fact-based content around 
he safety and effectiveness of vaccines. 
COVID-19 vaccine hesitancy is particularly prevalent amongst 
arginalized groups who have been worst impacted by the pan- 
emic. Surveys in the UK [86] , US [87] , and many other coun- 
ries have shown that respondents from Black, Asian, and minor- 
ty ethnic (BAME) backgrounds are less likely to accept the vac- 
ine compared to White counterparts. Some of this hesitancy and 
istrust of the medical profession more broadly is likely grounded 
n a long history of structurally racist systems which have led to 
ealth inequalities and injustices. Furthermore, individuals from 
AME backgrounds make up a disproportionate amount of low- 
aid, shift-working, frontline workers, so access barriers and in- 
onveniences in attending jab appointments may also contribute 
o lack of vaccine uptake. To address this, vaccination appoint- 
ents should be available at flexible times outside of traditional 
ork hours [88] . Additionally, it must be acknowledged that vac- 
ine rollout strategies are not one-size-fit-all; they should be sen- 
itive to the contexts of local communities, and inclusive of local 
ommunity leaders (religious leaders, etc.) to engender trust and 
igher vaccine acceptance [88–90] . Science plus approaches, where 


























































































































here is engagement and dialog with vaccine hesitant individuals 
nd communities to better understand and address their concerns 
round vaccines can be successful in improving uptake [91 , 92] . 
“First-mover” effect, or hesitancy caused by presumed risks as- 
ociated with the first vaccines, may also discourage uptake by 
ersons who normally receive immunizations [93] . Though false, 
any worry that corners have been cut in terms of safety because 
f the unprecedented speeds at which the first COVID-19 vaccines 
ere developed. It is vital that any vaccine that comes to mar- 
et has been thoroughly tested and held to high safety standards 
o build public confidence; and if any issues do arise, regulators 
hould react quickly. For example, British authorities quickly issued 
ecommendations against the use of the Pfizer/BioNTech vaccine in 
ndividuals with a history of serious allergies after two severe al- 
ergic reactions were observed in the first weeks of the vaccine’s 
eployment in the US and the UK [94] . Once further data was col-
ected, the agency determined that individuals with a history of 
naphylaxis could be vaccinated, after all, and vaccine guidance 
as updated accordingly [39] . 
Furthermore, interventions to overcome vaccine hesitancy must 
e evidence-based. Some studies have demonstrated that interven- 
ions which facilitate vaccination directly (e.g., reminders, man- 
ates) are more effective than those that seek to change what 
eople think and feel (e.g., education campaigns, motivational in- 
erviewing) [95] . While it may be constitutionally or politically 
mpossible for some countries to impose national vaccine man- 
ates, there may be other influences (e.g. vaccine passports for 
ravel) that make vaccination a de facto requirement in everyday 
ife (discussed in further detail below). For those who remain un- 
onvinced even with private-sector vaccine requirements, they may 
e swayed by celebrity vaccination campaigns [96] or by the intro- 
uction of ‘opt out’ policies where the default is to vaccinate [97] . 
.4. Ethical implications of vaccine passports and other vaccine 
equirements 
Ethical considerations must be made at every step of the vac- 
ine development, distribution, and deployment processes; how- 
ver, debates have particularly grown around the potential imple- 
entation of vaccine mandates and vaccine passports. Private com- 
anies may require evidence of prior COVID-19 vaccination before 
ustomers can use their services [98] . For example, Qantas has an- 
ounced that in the future, their travelers will need to prove that 
hey have been vaccinated against COVID-19 before boarding inter- 
ational flights [99] . Countries such as Greece and Israel are also 
rming plans to launch vaccine passports [100] . Furthermore, some 
mployers are considering policies which would require all newly 
ired staff to have the jab [101] . This has opened a slew of ethical
uestions and the weighing of benefits to society vs. those for the 
ndividual. Of course, we need populations to be widely vaccinated 
o return to ‘normal’ life and make up for over a year of losses 
ue to halts in economic activity, travel, education, etc. However, 
accine requirements could pit those who are further down in the 
accination queue against those who are already inoculated: those 
rom poor countries against richer ones; younger, healthier peo- 
le against older, multi-morbid ones; pregnant women and moth- 
rs and individuals from minority ethnic backgrounds, against their 
ale/White counterparts. Vaccine passports for travel may also 
equire interoperable digital data systems, which will create fur- 
her complexities around international law and trust. Governments 
hould seriously consider all the ethical dimensions when making 
ecisions around vaccine mandates or passports for travel, employ- 
ent, and beyond. If vaccine passports or requirements are indeed 
mplemented, there should also be stipulations for individuals who 
annot be immunized for various reasons (immunocompromised, 
regnant, etc.). 562 Currently, no vaccine is authorized for use in children. But if 
his changes, even more ethical challenges will arise. For exam- 
le, it remains to be seen whether schools will require children 
o be vaccinated to attend as a mechanism to protect fellow stu- 
ents, teachers, and the school communities at large. Additionally, 
f vaccine passports are implemented, it remains unclear whether 
here will be exemptions for children, or whether this would mean 
hat they (and their accompanying parents/guardians) will be un- 
ble to travel unless regulatory authorizations change. Vaccine hes- 
tancy is already an issue in the adult population, but it may prove 
ven stronger for adults making decisions about vaccinating their 
hildren, especially considering that the side effects of the jabs 
fever, lethargy, etc.) may be more severe than COVID-19 infection 
n children (on average). Without vaccinating children, who make 
p about 30% of the global population, against COVID-19, it is un- 
ikely that we can achieve global herd immunity to the illness via 
 vaccine. Thus, ethical considerations on the value of global herd 
mmunity and protecting the greater good must be made alongside 
hose on the value of the freedom of choice in healthcare decision- 
aking. 
.5. Adapting clinical and health research systems 
Not only will governments need to vaccinate as much of their 
opulations as quickly as possible to tackle the current pandemic, 
ut they will also need to maintain high rates of immunization 
gainst COVID-19 in the years ahead. Mass immunization cam- 
aigns need to be conducive to storage and distribution require- 
ents for the vaccines themselves and avoid placing individuals 
t increased risk for infection. Public facilities with space for safe 
hysical distancing measures (e.g. stadiums, cathedrals) and ade- 
uate power supplies in the case of cold chain storage may be 
sed. Additionally, the workforce able to administer the vaccines 
ill need to be boosted to support the tens of billions of vaccine 
ose administrations required. Healthcare systems can be creative 
nd may look beyond doctors and nurses for this job. Furthermore, 
olunteers may be able to take on non-clinical tasks, such as di- 
ecting patients, sanitizing waiting areas, and dolling out second 
ppointment cards, to help vaccination rollout run smoothly. 
A major concern in clinical systems is the administrative bur- 
en that the vaccines will have with their need for strong record 
eeping. Many of the first-generation vaccines require two doses 
paced apart at set intervals which presents logistical challenges, 
specially in places without strong record keeping systems. Fur- 
hermore, we still do not know how long immunity from COVID-19 
accines will last, and whether vaccine booster types can be mixed 
nd matched. Emerging evidence suggests that just one dose of 
hese two-dose vaccines may offer protection for those with pre- 
ious COVID-19 infection [102 , 103] . Currently, however, the WHO 
as not listed any recommendations to test for COVID-19 antibod- 
es before administering a vaccine. Thus, someone who may have 
lready had the virus is still advised to get vaccinated when it is 
heir ‘turn’ on the list. As the science develops and there becomes 
ore clarity around how long immunity levels last after previous 
nfection, this guidance could change. France’s health authority, for 
xample, issued recommendations in February that anyone previ- 
usly infected with COVID-19 only receive one vaccine jab (even 
or vaccines in which two doses is standard); however, the agency 
id not issue any guidance on how it would determine who had 
lready contracted COVID-19 and when [104] . 
Thus, providers of all specialties should be incentivized to mon- 
tor their patients’ immunization histories and ensure vaccines are 
p-to-date, particularly if booster shots are required [95] . Phase 4 
urveillance data could be made accessible to clinicians through 
ublicly accessible platforms. Reporting systems can be finetuned 











































11 COVID-19 vaccine policy challenges. 
CHALLENGE CURRENT ISSUES, POLICIES & PRACTICES CONSIDERATIONS FOR THE FUTURE FINANCING → ETHICS → 
Ensuring continued development of safe and effective vaccines 
1. Maintaining strong and sensible R&D incentives • Direct grants, pre-purchasing agreements, 
and other financing mechanisms which do not 
attach strings to vaccine success outcomes 
• Innovative financing mechanisms such as 
the Options Market for Vaccines (OMV) 
2. Running coordinated clinical trials • Differences in organizing/reporting clinical 
trials between countries 
• Issues related to diversity (age, 
race/ethnicity) of clinical trial participants 
• WHO proposal for a Solidarity Vaccine Trial 
• EU Clinical Trials register 
• Uniform clinical trial criteria (including 
endpoints) could be developed 
• Diverse sample of participants should be 
included in trials 
Clinical trials for future vaccine candidates 
should be flexible 
3. Authorizing safe and effective vaccines efficiently and transparently: • Regulatory timelines, guidance, and 
processes vary across countries 
• Some agencies have authorized vaccines 
without stage III trial data 
• Initial guidance around vaccines in older 
adults and pregnant women varied between 
regulatory bodies 
• Regulatory guidance for vaccine 
modifications to address new variants differs 
across agencies 
• Further alignment on regulatory processes 
is needed across jurisdictions 
• Regulatory agencies should use same units 
and end points 
• Transparency and efficiency 
• Further alignment on fast-tracking 
COVID-19 vaccine updates to address new 
variants 
4. Monitoring effectiveness during (and after) vaccine deployment • Domestic effort s to monitor vaccines that 
have been administered; but mainly 
independently run studies 
• Consensus around the most useful 
post-market surveillance measures and how 
to report data in real-time to other nations 
• International body, such as the WHO, could 
coordinate efforts of monitoring studies 
around the globe 
Supplying and disseminating the vaccine around the world 
5. Ensuring equitable vaccine access globally • Vaccine nationalism 
• COVAX has made significant achievements, 
but much more funding is needed 
• Countries are paying widely different prices 
for the same products 
• Some HICs have committed to donating any 
extra vaccine doses to LMICs 
• Global solidarity needed; COVID-19 is a 
threat to us all until everyone has access to a 
vaccines 
• Greater investment in COVAX with 
guaranteed funding of $20-40 billion for 2021 
• Innovative R&D financing models could link 
product price to the initial investments made 
and risk taken by a purchaser 
• Plans should be established for COVID-19 
donation processes 
• Vaccine donations should be concurrent 
with national vaccination rollout 
6. Manufacturing sufficient quantities and maintaining supply chain capacity: • Disruptions in the vaccine supply chain; 
delivery delays 
• Some technology transfer agreements 
• Cold chain requirements and ultra-cold 
chain requirements create logistical barriers –
especially for LMICs 
• Increasing concern around bottlenecks and 
shortages in supply chain equipment (e.g. 
vials, labels) 
• Additional technology transfers between 
private companies 
• Joint patent purchases for COVID-19 
vaccines 
• Compulsory licensing could be used to 
enable governments to gain control over 
production 
• Increased cooperation between 
governments and private industry 
• Removal of export bans on vaccines and 
supply chain equipment 
• Gavi Board to bring co-investors on board 
to aid in building cold chain capacity in LMICs 














































Table 2 ( continued ) 
CHALLENGE CURRENT ISSUES, POLICIES & PRACTICES CONSIDERATIONS FOR THE FUTURE FINANCING → ETHICS → 
Deploying the vaccine within countries 
7. Safely and securely transporting and delivering vaccines • Global warnings about the potential for 
criminal activity aimed at infiltrating and 
disrupting COVID-19 vaccine supply chains 
• Freight companies already enhancing 
security 
• Continue security effort s and build new 
ones 
• Security systems should protect the cargo 
and the integrity of the cargo 
8. Determining fair vaccine allocation: • Most country allocation guidance prioritizes 
high-risk populations including elderly and 
co-morbid patients, critical health and social 
care workers 
• Determine prioritization within high-risk 
groups 
• Transparency around why some groups are 
placed higher on the list than others. 
• Equity considerations should be made 
across and within priority groups 
• Mechanisms should be established to 
capture groups that may otherwise be missed 
in prioritization schemes (e.g. undocumented 
migrants, homeless individuals) 
9. Encouraging the uptake of vaccines: • Vaccine hesitancy, particularly amongst 
marginalized groups 
• Anti-vax movement; fake news, 
misreporting, and an ‘infodemic’ 
• Many individuals believe vaccine was 
developed too quickly 
• Respond quickly, responsibly, and 
transparently if side-effects arise 
• Flexible vaccine appointment times (24 
hours) 
• Inclusive vaccination campaigns; engage 
community leaders; sensitive to community 
contexts 
• Science plus approaches; 
engagement/dialogue with vaccine hesitant 
people to understand/address concerns 
• Celebrity vaccination campaigns 
• Vaccine rollout strategies are not 
one-size-fits-all 
10. Ethical implications of vaccine passports and other vaccine requirements: • Ethical debates and concerns around 
vaccine passports, employer/school vaccine 
requirements, etc. 
• Some countries already launching vaccine 
passports 
• Digital vaccine passports require 
considerations about data interoperability and 
more 
• Ethical debates likely to increase if/when 
vaccines authorized in children 
• Ethical dimensions must be considered, 
explored, and understood 
• If vaccine passports or requirements are 
implemented, stipulations/exceptions need for 
those who cannot be immunized 
• Legal considerations around vaccine 
passports (data interoperability, forgery risks, 
etc.) must be made 
11. Adapting Clinical and Health Research Systems • Clinical system adaptations for vaccine 
campaigns underway in many countries 
• Several authorized vaccines require two 
doses, spaced evenly apart 
• The WHO does not currently recommend 
testing for antibodies for COVID-19 prior to 
administering a vaccine; France 
recommending previously infected individuals 
only receive one dose 
• Some countries have established real-time 
surveillance and genomic sequencing systems; 
but efforts are not generally coordinated on 
the international level 
• Public facilities with adequate opportunity 
for safe physical distancing measures and 
power supplies may be used for 
mass-administration clinics 
• Healthcare systems can be creative and 
build training programs to increase personnel 
for vaccine administration 
• Administrative capacity and incentive 
structures to facilitate record keeping needed 
• COVID-19 vaccine and raw material 
stockpiles for future outbreaks due to 
antigenic drift or shift 
• A global system based on the WHO’s Global 







































































ecurely report adverse health events associated with COVID-19 
accines. Furthermore, health systems must maintain appropriately 
ized stockpiles of COVID-19 vaccines and raw materials for future 
utbreaks due to antigenic drift or shift. 
Research systems also need to be adapted to efficiently detect 
irus mutations, share genetic sequencing globally, adjust existing 
accines, and develop new ones to respond to pathogens accord- 
ngly. Individual countries, such as the UK with its COG-UK, have 
ad success in establishing real-time surveillance and genomic se- 
uencing systems [105] . However, to be most successful, similar 
ystems should be developed around the world and with coordi- 
ation mechanisms between them. A global system based on the 
HO’s Global Influenza Surveillance and Response System (GISRS) 
hereby COVID-19 national research centers work under an agency 
ithin an international organization could be established so that 
OVID-19 epidemiology and genomic make-up can be monitored 
lobally and alerts about novel variants can be made quickly [106] . 
. Discussion 
From start to finish, numerous policy challenges remain around 
OVID-19 vaccines, as outlined in Table 2 . Estimates suggest that at 
east 60–70% of the population will need to be immune to COVID- 
9 to achieve herd immunity [107] . Furthermore, vaccines are vi- 
al components to the revitalization of economies and communi- 
ies that have been devastated by the impacts of COVID-19 [108] . 
hus, we must anticipate COVID-19 vaccine challenges and rec- 
gnize their interdependencies in order to build actionable plans 
nd ensure vaccine development, dissemination, and deployment. 
qually, we must be realistic in our expectations of COVID-19 vac- 
ines and their timelines given the multitude of barriers. 
Global scientific partnerships have played an essential role in 
he successful delivery of COVID-19 vaccines so far. Thus, one 
f the key takeaways from the COVID-19 vaccine experience is 
hat nationalistic approaches to immunization will not suffice, and 
lobal partnerships can be very successful and effective with the 
ight resources. We have witnessed a truly great scientific feat, but 
his is not the end of COVID-19 and there are many other areas of 
nmet therapeutic need that we have not addressed yet. We must 
ontinue to support and fund these global effort s. 
Luckily, a vaccine is not the only weapon against COVID-19 in 
ur arsenal. Already, we have witnessed how successfully imple- 
enting non-pharmaceutical interventions, such as social distanc- 
ng and mask wearing, can mitigate the spread of infection (al- 
hough they do prevent complete re-opening of economies) [109] . 
e have also developed a deeper understanding of COVID-19 since 
t first emerged at the end of 2019, and identified several ther- 
peutics to reduce risk of mortality in patients with the illness 
110 , 111] . The successful vaccines that are emerging in the fight 
gainst COVID-19 are extraordinary developments, however they 
re just one tool in our shed of mechanisms to combat COVID-19, 
ather than a replacement of NPI and therapeutic methods. 
The journey from vaccine discovery to global herd immunity 
gainst COVID-19 presents significant policy challenges that require 
ollaborative, global responses. Despite the great success in bring- 
ng multiple vaccine candidates to market in under a year, there 
re still many challenges ahead for achieving herd immunity even 
t a national level, and much more so for achieving this at the 
lobal level. Decision-makers must be aware of these challenges 
nd begin strategizing solutions that can be implemented at scale. 
nly then will the global public health community end this pan- 
emic, while emerging prepared for the next. 
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